Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs01:25

Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs

435
Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
435
Antiasthma Drugs: Leukotriene Modifiers01:19

Antiasthma Drugs: Leukotriene Modifiers

442
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
442
Asthma: Pathogenesis and Management01:20

Asthma: Pathogenesis and Management

562
Asthma is a chronic pulmonary condition involving inflammation of the airways, hyper-reactivity, and reversible obstruction of the airways. This condition can significantly impact a person's quality of life, making breathing difficult and leading to distressing symptoms.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
562
Asthma-IV: Diagnostic and Management01:30

Asthma-IV: Diagnostic and Management

2.6K
The diagnosis and management of asthma are comprehensive, encompassing clinical assessments, lung function tests, and pharmacological interventions. Here's an overview:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
2.6K
Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids01:25

Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids

380
Inhaled corticosteroids (ICS) are anti-inflammatory drugs used primarily in treating persistent asthma and providing long-term maintenance. They target the bronchial mucosa, the lining of the airways, to control inflammation, a critical factor in asthma progression and exacerbation.
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
380
Asthma-II: Pathophysiology and Classification01:26

Asthma-II: Pathophysiology and Classification

2.8K
Asthma is a prevalent chronic respiratory condition marked by inflammation and hyperresponsiveness of the airways. Its pathophysiology involves complex interactions among inflammatory pathways, immune responses, and neural mechanisms.
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:
2.8K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

New Therapies for Sarcoidosis: Molecular and Pathophysiological Basis.

International journal of molecular sciences·2026
Same author

The Role of Dipeptidyl Peptidase Inhibitors in Pulmonary Diseases.

Biomedicines·2026
Same author

Adherence and Effectiveness of Positive Airways Pressure (PAP) Therapy in Obstructive Sleep Apnea (OSA) Patients Suffering from Mental Disorders.

Healthcare (Basel, Switzerland)·2026
Same author

The Impact of BMI on the Effect of Biologic Agents for Severe Asthma.

Pulmonary therapy·2026
Same author

Indoor Employment as a Factor Associated with Vitamin D Levels in Obstructive Sleep Apnoea Syndrome.

Medicina (Kaunas, Lithuania)·2026
Same author

The Natural History of Obstructive Sleep Apnea: A Scoping Review.

Healthcare (Basel, Switzerland)·2026

Related Experiment Video

Updated: Sep 6, 2025

Bronchial Thermoplasty: A Novel Therapeutic Approach to Severe Asthma
14:39

Bronchial Thermoplasty: A Novel Therapeutic Approach to Severe Asthma

Published on: November 4, 2010

32.0K

Biologic Therapies in Pediatric Asthma.

Evanthia P Perikleous1, Paschalis Steiropoulos2, Evangelia Nena3

  • 1Medical School, Democritus University of Thrace, 68100 Alexandroupoli, Greece.

Journal of Personalized Medicine
|June 24, 2022
PubMed
Summary

Biologic agents offer new hope for severe childhood asthma management, improving control and reducing exacerbations. Further research is needed on long-term use and optimal selection in pediatric patients.

Keywords:
asthmabiologic agentschildrenmonoclonal antibodiessevere asthma

More Related Videos

Dry Powder and Nebulized Aerosol Inhalation of Pharmaceuticals Delivered to Mice Using a Nose-only Exposure System
07:28

Dry Powder and Nebulized Aerosol Inhalation of Pharmaceuticals Delivered to Mice Using a Nose-only Exposure System

Published on: April 6, 2017

40.8K
Cultivate Primary Nasal Epithelial Cells from Children and Reprogram into Induced Pluripotent Stem Cells
12:08

Cultivate Primary Nasal Epithelial Cells from Children and Reprogram into Induced Pluripotent Stem Cells

Published on: March 10, 2016

11.3K

Related Experiment Videos

Last Updated: Sep 6, 2025

Bronchial Thermoplasty: A Novel Therapeutic Approach to Severe Asthma
14:39

Bronchial Thermoplasty: A Novel Therapeutic Approach to Severe Asthma

Published on: November 4, 2010

32.0K
Dry Powder and Nebulized Aerosol Inhalation of Pharmaceuticals Delivered to Mice Using a Nose-only Exposure System
07:28

Dry Powder and Nebulized Aerosol Inhalation of Pharmaceuticals Delivered to Mice Using a Nose-only Exposure System

Published on: April 6, 2017

40.8K
Cultivate Primary Nasal Epithelial Cells from Children and Reprogram into Induced Pluripotent Stem Cells
12:08

Cultivate Primary Nasal Epithelial Cells from Children and Reprogram into Induced Pluripotent Stem Cells

Published on: March 10, 2016

11.3K

Area of Science:

  • Pediatric Pulmonology
  • Immunology
  • Pharmacology

Background:

  • Childhood asthma is a complex chronic condition, with severe cases posing significant management challenges.
  • Biologic agents represent a promising advancement in precision medicine for treating severe, refractory asthma in children.
  • Current biologic treatments include omalizumab, mepolizumab, benralizumab, dupilumab, and tezepelumab, showing efficacy in asthma control and exacerbation reduction.

Purpose of the Study:

  • To review current evidence on licensed monoclonal antibodies for pediatric severe asthma.
  • To discuss the effectiveness, long-term use, and selection criteria for biologics in children.
  • To explore future therapeutic targets in childhood asthma management.

Main Methods:

  • Systematic review of current literature on biologic therapies for pediatric asthma.
  • Analysis of data from clinical trials and real-world evidence regarding approved monoclonal antibodies.
  • Discussion of extrapolated data from adult studies and identification of knowledge gaps.

Main Results:

  • Approved biologics demonstrate effectiveness in improving asthma control and decreasing exacerbation rates in children.
  • Limited long-term data exists for pediatric populations, often relying on adult study extrapolations.
  • Predictors of response and optimal long-term outcomes require further investigation in pediatric cohorts.

Conclusions:

  • Monoclonal antibodies are valuable add-on therapies for severe childhood asthma.
  • Long-term safety and efficacy data in children need further robust investigation.
  • Continued research is essential to refine biologic selection and identify future therapeutic strategies for pediatric asthma.